Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;109(2):255-262.
doi: 10.1007/s00392-019-01508-9. Epub 2019 Jun 18.

The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy

Affiliations

The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy

Michal Laufer-Perl et al. Clin Res Cardiol. 2020 Feb.

Abstract

Background: Cardiotoxicity is a leading cause of morbidity and mortality among patients receiving cancer therapy. The most commonly used definition is cancer therapy-related cardiac dysfunction (CTRCD) defined by a left ventricular ejection fraction reduction. Global longitudinal strain (GLS) has been implied to be superior in detecting early subclinical dysfunction.

Objectives: Evaluate the prevalence of reduced GLS and whether it is associated with CTRCD development among patients receiving cancer therapy.

Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients receiving different types of cancer therapy, who were referred to the cardio-oncology clinic. Patients were divided into two groups-reduced GLS (> - 17%) vs. preserved GLS (≤ - 17%). Multivariable analyses were adjusted for a propensity score for baseline characteristics.

Results: Among 291 consecutive patients, 48 (16%) patients were included in the reduced GLS group. Overall, 11 (5%) patients developed CTRCD at following echocardiogram evaluation. Patients with preserved GLS had a significantly lower risk for CTRCD development [odds ratio (OR) 0.11, 95% confidence interval (CI) 0.03-0.41, p = 0.001], with every 1-unit improvement of GLS the risk of CTRCD decreased by 16% (OR 0.84, 95%CI 0.73-0.95, p = 0.007). After adjustment for baseline characteristics, including cardiovascular risk factors and systolic function, preserved GLS remained significantly associated with a lower risk for CTRCD development (OR 0.11, 95%CI 0.02-0.64, p = 0.014), with every 1-unit improvement lowering the risk by 19% (OR 0.81, 95%CI 0.67-0.98, p = 0.032).

Conclusions: Reduced GLS is common among patients receiving cancer therapy and may identify patients at increased risk for CTRCD development.

Keywords: CTRCD; Cardio-oncology; Cardiotoxicity; GLS; Strain.

PubMed Disclaimer

References

    1. Clin Res Cardiol. 2019 Aug;108(8):892-900 - PubMed
    1. J Am Coll Cardiol. 2000 Apr;35(5):1237-44 - PubMed
    1. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68 - PubMed
    1. J Am Coll Cardiol. 2010 Jan 19;55(3):213-20 - PubMed
    1. Eur Heart J Cardiovasc Imaging. 2017 Apr 1;18(4):392-401 - PubMed

MeSH terms

Substances

LinkOut - more resources